Loading clinical trials...
Loading clinical trials...
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions
Interventions
Tisagenlecleucel
Lymphodepleting chemotherapy
Locations
26
United States
UCSF Medical Center .
San Francisco, California, United States
Emory University School of Medicine/Winship Cancer Institute SC CTL019
Atlanta, Georgia, United States
University of Chicago Medical Center Hematology and Oncology SC - CTL019B2207J
Chicago, Illinois, United States
University of Kansas Cancer Center SC - CTL019C2201
Westwood, Kansas, United States
Sidney Kimmel Comprehensive Cancer Center SC-2
Baltimore, Maryland, United States
Uni of Michigan Health System SC CTL019
Ann Arbor, Michigan, United States
Start Date
July 29, 2015
Primary Completion Date
December 22, 2022
Completion Date
December 22, 2022
Last Updated
April 18, 2024
NCT07397832
NCT06043011
NCT04488354
NCT05583149
NCT02570542
NCT07215832
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions